Results of a study by INMARK® suggest that early administration of antifibrosis therapy allows to slow down the progression of idiopathic pulmonary fibrosis. Scientific journal The Lancet Respiratory Medicine published the results of a randomized double-blinded study by INMARK®, which validated the effectiveness of Vargatef (nintedanib) versus placebo in patients with idiopathic pulmonary fibrosis (IPF)…